YAPALI, S. Et Al. 2022. Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421). EASL The International Liver Congress , (London, Canada).

YAPALI, S., GÖKCAN, H., DURAK, S., MELEKOĞLU ELLİK, Z., GÜZELBULUT, F., VATANSEVER, S., ... ARI, D.(2022). Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421) . EASL The International Liver Congress, London, Canada

YAPALI, SUNA Et Al. "Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421)," EASL The International Liver Congress, London, Canada, 2022

YAPALI, SUNA Et Al. "Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421)." EASL The International Liver Congress , London, Canada, 2022

YAPALI, S. Et Al. (2022) . "Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421)." EASL The International Liver Congress , London, Canada.

@conferencepaper{conferencepaper, author={SUNA YAPALI Et Al. }, title={Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis (SAT421)}, congress name={EASL The International Liver Congress}, city={London}, country={Canada}, year={2022}}